ReNeuron

ReNeuron is a UK-based stem cell research company whose shares were listed on the Alternative Investment Market, until it delisted in August 2024 after entering administration.^[1] Its focus is on the development of stem-cell therapies targeting areas of poorly-met medical need, including peripheral arterial disease, strokes, and retinal diseases.

ReNeuron

Company type	Public company
Traded as	LSE: RENE
Industry	Stem cell research & development
Founded	1997
Headquarters	Surrey, England, UK
Key people	chairman = Trevor Jones
Website	reneuron.com

As of 2010 ReNeuron was testing the effects of neural stem cells on spinal cords for neuroregeneration.^[2] They were also testing the use of fetal stem cells on stroke patients.^[3]